Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 30 June 2017 | By Zachary Brennan
The US Centers for Medicare and Medicaid Services (CMS) on Friday released 2016 data on more than $8 billion in payments (which is on par with 2015 data) made by 1,481 pharmaceutical, biotech and medical device companies to more than 600,000 physicians and 1,146 hospitals.
In total, CMS calculated that $2.8 billion was spent on general payments and $4.36 billion on research payments.
In its breakdown of the numbers, CMS says that more than $1 billion in 2016 was spent on physicians for speaking, training and education engagements that are not for continuing education, and on royalties or other payments based on sales of products that use a physician’s intellectual property.
And more than $430 million in 2016 was spent on food, beverages, travel and lodging, which compares to about $440 million in 2015.
The database also breaks down the figures by company, though some of the multinational biopharmaceutical companies, like Roche and Johnson & Johnson, did not disclose complete numbers that matched their peers for 2016. The following is a breakdown of what was listed for some of the largest companies (in alphabetical order):
Tags: CMS open payments, drug industry payments to doctors
Regulatory Focus newsletters
All the biggest regulatory news and happenings.